Trial · NCT00869206
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization | 2 years | All patients that were eligible and completed treatment were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Average Pain Intensity Score as Assessed by the Brief Pain Inventory (BPI) Questionnaire | from baseline up to 2 years | 1766 patients completed treatment and were analyzed. | score on a scale | MEAN |
| SECONDARY | Average ECOG Performance Status | from baseline up to 2 years | 1766 patients completed treatment and were analyzed. | score on a scale | MEAN |
| SECONDARY | Incidence of Osteonecrosis of the Jaw | from baseline up to 2 years | 1766 patients completed treatment and were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Incidence of Renal Dysfunction | from baseline up to 2 years | 1689 patients completed treatment and were analyzed. | percentage of participants | NUMBER |
| SECONDARY | Skeletal Morbidity Rate | from baseline up to 2 years | 1766 patients were treated and analyzed. | SRE's per year | MEAN |
| SECONDARY | Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Breast Cancer) | from baseline up to 2 years | 266 breast cancer patients who were treated and included in this portion of the substudy. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Breast Cancer | from baseline up to 24 months | 820 patients completed treatment and were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Prostate Cancer | from baseline up to 24 months | 660 patients completed treatment and were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Multiple Myeloma | from baseline up to 24 months | 265 patient completed treatment and were analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Prostate Cancer) | from baseline up to 24 months | 207 prostate cancer patients who were treated and included in this portion of the substudy. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Multiple Myeloma) | from baseline up to 24 months | 74 multiple myeloma patients were treated and included in this portion of the substudy. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00869206/outcomes